<SEC-DOCUMENT>0001140361-25-041225.txt : 20251110
<SEC-HEADER>0001140361-25-041225.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110060426
ACCESSION NUMBER:		0001140361-25-041225
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251108
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330336973
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		251464148

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20058520_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ions="http://ionis.com/20251108" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_37b826f8738d40f093d8e21c9182402c" contextRef="c20251108to20251108" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_ef8756b2a2ef48df92e36933c0ad4288" contextRef="c20251108to20251108">0000874015</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ions-20251108.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20251108to20251108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-08</xbrli:startDate><xbrli:endDate>2025-11-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C.&#160; 20549</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_05178892be8e439aabbac556977de5f1" contextRef="c20251108to20251108">8-K</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PURSUANT TO SECTION 13 OR 15(d) OF THE</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_347187cf8e3f452888a458032fbbee5c" contextRef="c20251108to20251108" format="ixt:date-monthname-day-year-en">November 8, 2025</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_91df589377b44bddb2c13d3fbf01b938" contextRef="c20251108to20251108">IONIS PHARMACEUTICALS, INC.</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Exact Name of Registrant as Specified in Charter)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_1e4475d2a0ac40da8bba94b401cfeb49" contextRef="c20251108to20251108" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or Other Jurisdiction of Incorporation)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_5c5b1c588ba74e31a6d20bd1ad247fcc" contextRef="c20251108to20251108">000-19125</ix:nonNumeric><br/>
              </div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_57264044a1cd4fda8f637207729cdbc2" contextRef="c20251108to20251108">33-0336973</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;">(Commission File No.)</div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_aaf639dcf89844ae90d0b94bf4aab50e" contextRef="c20251108to20251108">2855 Gazelle Court</ix:nonNumeric><br/>
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_1271793cb5dc49f4b7e901e82f1636d4" contextRef="c20251108to20251108">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_81e71eb71a264fad8a2b4493bc9db53b" contextRef="c20251108to20251108">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_578572ce062d4e1fabb812e2ae2da0dd" contextRef="c20251108to20251108">92010</ix:nonNumeric></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Address of Principal Executive Offices and Zip Code)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_3fae0ecd90c34a2ca4e5069fcd85b48d" contextRef="c20251108to20251108">760</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_c85a84bb1c5b406184a86f22d424e44a" contextRef="c20251108to20251108">931-9200</ix:nonNumeric></span></div>

        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;"> <br/>
          </span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions:</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_63ac4ec396c845a29951e4ff73af8d5b" contextRef="c20251108to20251108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: middle; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_ab125850fa7a4d6c930ab30600fba0af" contextRef="c20251108to20251108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_aac0b40c95ab4fb8b15eafa6642d8469" contextRef="c20251108to20251108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_40fe8b118416410e92196a5a2a278dad" contextRef="c20251108to20251108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 31.1%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Title of each class</div>
            </td>

    <td style="width: 4.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 17.22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Trading symbol</div>
            </td>

    <td style="width: 4.57%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 42.41%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 31.1%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_423e1f035e3d45a792e5ba004bf305d4" contextRef="c20251108to20251108">Common Stock, $.001 Par Value</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 4.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 17.22%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_83c39807ed884f4b86170a1d4278c3be" contextRef="c20251108to20251108">&#8220;IONS&#8221;</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: 4.57%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 42.41%; vertical-align: top;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_f82124cde5d642b38793d066fee4d151" contextRef="c20251108to20251108" format="ixt-sec:exchnameen">The Nasdaq Stock Market, LLC</ix:nonNumeric><br/>
              </div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
        Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</div>

      <div style="text-align: right; text-indent: 288pt; font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;</div>

      <div style="text-align: right; text-indent: 288pt; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_9627e1bb0d8346f1b94d0a2a0cd0096e" contextRef="c20251108to20251108" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="color: rgb(0, 0, 0);"> &#160; &#9744;</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/> </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 7.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="font-weight: bold;">Regulation FD Disclosure.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On November 8, 2025, Ionis Pharmaceuticals, Inc.&#160; (&#8220;Ionis,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our company&#8221;) issued a press release announcing positive results from the pivotal Phase 3
        CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (&#8220;sHTG&#8221;).&#160; A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The information in this Item 7.01 and the exhibit attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as
        amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
        incorporation language in such filing.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="font-weight: bold;">Other Events.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On November 8, 2025, we announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with sHTG. The studies met the primary
        endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six months. The reductions were sustained through 12 months. Olezarsen showed a highly
        statistically significant 85% reduction in acute pancreatitis events, the first and only time achieved in sHTG. Additionally, 86% of olezarsen-treated patients achieved triglyceride levels less than 500 mg/dL, below the risk threshold for acute
        pancreatitis. Olezarsen demonstrated favorable safety and tolerability.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">These data were presented during a late-breaking session at the American Heart Association Scientific Sessions, taking place November 7-10 in New Orleans, and
        simultaneously published in <span style="font-style: italic;">The New England Journal of Medicine</span>.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Nearly 1,100 patients were enrolled in the CORE and CORE2 studies, which is the largest pivotal program ever conducted in sHTG, and patients were required to be on
        standard of care lipid-lowering therapy. The CORE and CORE2 studies met the primary endpoint across doses, with olezarsen demonstrating an up to 72% (p&lt;0.001) placebo-adjusted mean reduction in fasting triglyceride levels at six months. The
        reductions were sustained through 12 months. Additionally, among patients with baseline levels above these thresholds at 12 months:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">TGs &lt;880 mg/dL:</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> 89% and
                  88% of patients on olezarsen 50 mg and 80 mg, respectively, achieved triglyceride levels less than 880 mg/dL, the level associated with the highest risk of acute pancreatitis.</span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">TGs &lt;500 mg/dL:</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> 86% of
                  patients on olezarsen 50 mg and 80 mg achieved triglyceride levels less than 500 mg/dL, below the risk threshold for sHTG and acute pancreatitis.</span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">TGs &lt;150 mg/dL:</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> 34% and
                  54% of patients on olezarsen 50 mg and 80 mg, respectively, achieved normal triglyceride levels less than 150 mg/dL.</span></div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen demonstrated a highly statistically significant 85% reduction in adjudicated acute pancreatitis events at 12 months (p&lt;0.001). These results were based on
        a total of 22 events in 17 patients in the placebo group, compared to seven events in five patients in the olezarsen group.</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>In an overall pooled analysis of the number of patients needed to treat, treating 20 patients with olezarsen is estimated to prevent one acute pancreatitis event over one year.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>In the highest risk group, patients with triglyceride levels greater than or equal to 880 mg/dL and a history of acute pancreatitis, treating four patients is estimated to prevent one event over one year.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen also showed an overall favorable lipid profile, with significant reductions in the secondary endpoints of apoC-III, remnant cholesterol and non-HDL-C.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen demonstrated a favorable safety and tolerability profile in the CORE and CORE2 studies. Adverse events were balanced across treatment arms (75% olezarsen 50
        mg; 76% olezarsen 80 mg; 75% placebo). Serious adverse events occurred less frequently in the olezarsen group compared to placebo (9% olezarsen 50 mg; 11% olezarsen 80 mg; 14% placebo). The most common treatment-emergent events were injection site
        reactions, which were mostly mild and occurred more frequently with olezarsen (10% olezarsen 50 mg; 17% olezarsen 80 mg; 1% placebo).</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Several additional parameters were generally consistent with previous study results. At the 80 mg dose, asymptomatic increases in liver enzymes &#8805;3 times the upper
        limit of normal occurred in 7% of patients compared to 2% in the placebo group. These were not associated with clinical complications and generally resolved with continued dosing. No cases met the criteria for Hy&#8217;s law. Consistent with previously
        reported results with apoC-III-targeting therapies, small absolute mean elevations in liver fat (2.28% olezarsen 50 mg; 4.18% olezarsen 80 mg; 0.14% placebo) and hemoglobin A1c (HbA1c) (0.25% olezarsen 50 mg; 0.24% olezarsen 80 mg;
        placebo-adjusted) were observed. Increases in liver fat were not correlated with transaminase elevations and were not associated with clinical sequelae. There were no imbalances in HbA1c in non-diabetic patients.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">We are on track to submit a supplemental new drug application for both the 50 mg and 80 mg doses to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) by the end of the
        year and expect a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) target action date in 2026. We also anticipate making additional regulatory filings outside the U.S. next year. An open-label extension (&#8220;OLE&#8221;) study of olezarsen for sHTG is ongoing. More
        than 90% of patients who completed CORE and CORE2 chose to continue into the OLE.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include,
        without limitation, statements regarding Ionis&#8217; business, the therapeutic and commercial potential of olezarsen, our commercial medicines, additional medicines in development and technologies, and Ionis&#8217; expectations regarding development and
        regulatory milestones. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to
        identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, Ionis claims the protection of the safe harbor for forward-looking statements contained in the Private
        Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Ionis&#8217; expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to,
        risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.
        Ionis&#8217; forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Additional factors that
        could cause actual results to differ materially from those stated or implied by Ionis&#8217; forward-looking statements are disclosed in Ionis&#8217; filings with the Securities and Exchange Commission, including in the section captioned &#8220;Risk Factors&#8221; in
        Ionis&#8217; most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q. These forward-looking statements represent Ionis&#8217; judgment as of the time of this report. Ionis disclaims any intent or obligation to update these
        forward-looking statements, other than as may be required under applicable law.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits.</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 12%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 86%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a href="ef20058520_ex99-1.htm">99.1</a></div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 86%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">Press Release dated November 8, 2025.</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 12%; vertical-align: top;"><br/>
            </td>

    <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td rowspan="1" style="width: 86%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;">104</div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 86%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
            </td>

  </tr>


</table>
      <div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br/>
        </span></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">SIGNATURE</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td colspan="1" style="width: 49.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td colspan="2" rowspan="1" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; font-variant: small-caps; font-weight: bold;">Ionis Pharmaceuticals, Inc.</div>
            </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 49.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

  </tr>

  <tr>

    <td rowspan="1" colspan="1" style="width: 49.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify;">Dated:&#160; November 10, 2025</div>
            </td>

    <td rowspan="1" style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: justify;">By:&#160;&#160;<span style="text-decoration: underline;"></span></div>
            </td>

    <td rowspan="1" style="width: 47%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Patrick R. O&#8217;Neil</td>

  </tr>

  <tr>

    <td colspan="1" style="width: 49.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify; font-variant: small-caps; font-weight: bold;">Patrick R. O&#8217;Neil</div>
            </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 49.7%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </td>

    <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: justify;">Executive Vice President, Chief Legal Officer and General Counsel</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20058520_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <div>
    <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="font-size: 10pt; text-align: right; font-weight: bold;">Exhibit 99.1<br>
      </div>
      <div style="font-size: 10pt; text-align: left; font-weight: bold;"> <br>
      </div>
      <div style="font-size: 10pt; text-align: left; font-weight: bold;"><img src="image00001.jpg">
        <div><br>
        </div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions</div>
      <div style="font-size: 10pt; text-align: center;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#8211; Up to 72% placebo-adjusted mean reduction in fasting triglyceride levels at six months, with reductions sustained through 12 months &#8211;</div>
      <div style="font-size: 10pt; text-align: center;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#8211;&#160; 86% of olezarsen-treated patients achieved triglyceride levels less than 500 mg/dL, below the risk threshold for acute pancreatitis <font style="font-family: 'Times New Roman';">&#8211;</font></div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#8211; First and only investigational treatment for sHTG to significantly reduce acute pancreatitis events <font style="font-family: 'Times New Roman';">&#8211;</font></div>
      <div style="font-size: 10pt; text-align: center;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#8211; Data simultaneously published in <font style="font-family: 'Times New Roman'; font-style: italic;">The New England Journal of Medicine</font>&#160;<font style="font-family: 'Times New Roman';">&#8211;</font></div>
      <div style="font-size: 10pt; text-align: center;"><br>
      </div>
      <div style="text-align: center; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">&#8211; Ionis to host webcast today at 3:00 p.m. ET <font style="font-family: 'Times New Roman';">&#8211;</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">CARLSBAD, Calif., Nov. 8, 2025 -- <font style="font-family: 'Times New Roman';"><u>Ionis Pharmaceuticals, Inc.</u></font> (Nasdaq: IONS) today announced positive results
        from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in
        fasting triglyceride (TG) levels of up to 72% at six months. The reductions were sustained through 12 months. Olezarsen showed a highly statistically significant 85% reduction in acute pancreatitis events, the first and only time achieved in sHTG.
        Additionally, 86% of olezarsen-treated patients achieved triglyceride levels less than 500 mg/dL, below the risk threshold for acute pancreatitis. Olezarsen demonstrated favorable safety and tolerability.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">These data were presented today during a late-breaking session at the American Heart Association (AHA) Scientific Sessions, taking place November 7-10 in New Orleans, and
        simultaneously published in <font style="font-family: 'Times New Roman'; font-style: italic;">The New England Journal of Medicine.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;CORE and CORE2 are the first studies to show a significant reduction in acute pancreatitis events in sHTG, with most patients on olezarsen achieving
        triglyceride levels below the risk threshold for these potentially life-threatening episodes,&#8221; said Nicholas Marston, M.D., M.P.H, presenting author, cardiologist, Brigham and Women&#8217;s Hospital, Harvard Medical School. &#8220;As a lipid specialist who
        takes care of sHTG patients, I have seen the major consequences of acute pancreatitis, including cases with recurrent events requiring frequent hospitalizations. Given the modest effects of conventional therapies, these impactful data are a welcome
        advance and underscore the potential of olezarsen to transform the way we treat sHTG.&#8221;</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Nearly 1,100 patients were enrolled in the CORE and CORE2 studies, which is the largest pivotal program ever conducted in sHTG, and patients were required to be on
        standard of care lipid-lowering therapy. The CORE and CORE2 studies met the primary endpoint across doses, with olezarsen demonstrating an up to 72% (p&lt;0.001) placebo-adjusted mean reduction in fasting triglyceride levels at six months. The
        reductions were sustained through 12 months. Additionally, among patients with baseline levels above these thresholds at 12 months:</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader" style="width: 100%;">
          <div><img src="image00001.jpg"><br>
          </div>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc79ad4e5c15c4b8587863f779a8cacab">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">TGs &lt;880 mg/dL:</font><font style="font-size: 10pt;"> 89% and 88% of patients on olezarsen 50
                  mg and 80 mg, respectively, achieved triglyceride levels less than 880 mg/dL, the level associated with the highest risk of acute pancreatitis.</font></div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z75d13406209c47a5a8297e1ebbe3aa67">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">TGs &lt;500 mg/dL:</font><font style="font-size: 10pt;"> 86% of patients on olezarsen 50 mg and 80
                  mg achieved triglyceride levels less than 500 mg/dL, below the risk threshold for sHTG and acute pancreatitis.</font></div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9f76c192b3ea4274a66e03fcf8d6dc0c">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">TGs &lt;150 mg/dL:</font><font style="font-size: 10pt;"> 34% and 54% of patients on olezarsen 50
                  mg and 80 mg, respectively, achieved normal triglyceride levels less than 150 mg/dL.</font></div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen demonstrated a highly statistically significant 85% reduction in adjudicated acute pancreatitis events at 12 months (p&lt;0.001). These results were based on a
        total of 22 events in 17 patients in the placebo group, compared to seven events in five patients in the olezarsen group.</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z72164db9a0664de5880683c47c2b13e8">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">In an overall pooled analysis of the number of patients needed to treat (NNT), treating 20 patients with olezarsen is estimated to prevent one acute pancreatitis event over one year.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z48b52648f3774d05ae20b880458319f9">

          <tr>
            <td style="width: 18pt; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
              <div style="font-family: 'Times New Roman';">In the highest risk group, patients with triglyceride levels greater than or equal to 880 mg/dL and a history of acute pancreatitis, treating four patients is estimated to prevent one event over
                one year.</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen also showed an overall favorable lipid profile, with significant reductions in the secondary endpoints of apoC-III, remnant cholesterol and non-HDL-C.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Building on olezarsen&#8217;s success in treating familial chylomicronemia syndrome, a rare form of sHTG, these groundbreaking results position us to reach a significantly
        larger patient population who remain at risk of dangerous acute pancreatitis attacks,&#8221; said Brett P. Monia, Ph.D., chief executive officer, Ionis. &#8220;Olezarsen will be one of two independent launches for Ionis in 2026, our first in a broad population
        if approved, and is a powerful example of how we are turning groundbreaking science into meaningful medicines that have the potential to change lives.&#8221;</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen demonstrated a favorable safety and tolerability profile in the CORE and CORE2 studies. Adverse events were balanced across treatment arms (75% olezarsen 50 mg;
        76% olezarsen 80 mg; 75% placebo).<font style="font-family: 'Times New Roman';">&#160;</font>Serious adverse events occurred less frequently in the olezarsen group compared to placebo (9% olezarsen 50 mg; 11% olezarsen 80 mg; 14% placebo). The most
        common treatment-emergent events were injection site reactions, which were mostly mild and occurred more frequently with olezarsen (10% olezarsen 50 mg; 17% olezarsen 80 mg; 1% placebo).</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Several additional parameters were generally consistent with previous study results. At the 80 mg dose, asymptomatic increases in liver enzymes &#8805;3 times the upper limit
        of normal occurred in 7% of patients compared to 2% in the placebo group. These were not associated with clinical complications and generally resolved with continued dosing. No cases met the criteria for Hy&#8217;s law. Consistent with previously
        reported results with apoC-III-targeting therapies, small absolute mean elevations in liver fat (2.28% olezarsen 50 mg; 4.18% olezarsen 80 mg; 0.14% placebo) and hemoglobin A1c (HbA1c) (0.25% olezarsen 50 mg; 0.24% olezarsen 80 mg;
        placebo-adjusted) were observed. Increases in liver fat were not correlated with transaminase elevations and were not associated with clinical sequelae. There were no imbalances in HbA1c in non-diabetic patients.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader" style="width: 100%;">
          <div><img src="image00001.jpg"><br>
          </div>
        </div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis is on track to submit a supplemental new drug application for both the 50 mg and 80 mg doses to the FDA by the end of the year. An open-label extension (OLE) study
        of olezarsen for sHTG is ongoing. More than 90% of patients who completed CORE and CORE2 chose to continue into the OLE.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Webcast</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis will host a webcast to discuss the results from the CORE and CORE2 studies on Saturday, November 8 at 3:00 p.m. ET. Interested parties may access the webcast <u><font style="font-family: 'Times New Roman';">here</font></u>. A webcast replay will be available for a limited time.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About the CORE and CORE2 Studies</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">CORE (<u><font style="font-family: 'Times New Roman';">NCT05079919</font></u>; n=617) and CORE2 (<u><font style="font-family: 'Times New Roman';">NCT05552326</font></u>;
        n=446), conducted with The TIMI Study Group, are Phase 3 global, multicenter, randomized, double-blind, placebo-controlled trials investigating the safety and efficacy of olezarsen for severe hypertriglyceridemia (sHTG). Participants aged 18 and
        older with triglyceride levels &#8805;500 mg/dL<font style="font-family: 'Times New Roman';">&#160;</font>were enrolled. Participants were required to be on standard of care therapies for elevated triglycerides. At baseline, 47% and 37% of participants had
        baseline fasting triglycerides &#8805;880 mg/dL in CORE and CORE2, respectively. Participants were randomized to receive 50 mg or 80 mg of olezarsen or placebo every 4 weeks via subcutaneous injection for 12 months. The primary endpoint is the percent
        change from baseline in fasting triglycerides at six months compared to placebo.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Severe Hypertriglyceridemia</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Severe hypertriglyceridemia (sHTG) is defined by severely high triglycerides (<font style="font-family: 'Times New Roman';">&#8805;</font>500 mg/dL) and characterized by an
        increased risk of acute pancreatitis and other morbidities. Considered a medical emergency, acute pancreatitis causes debilitating abdominal pain that often requires prolonged hospitalization, can lead to permanent organ damage and can become
        life-threatening. Preventing the first attack is key. In people with a history of acute pancreatitis episodes, the risk of future attacks is even greater. Current standard of care therapies for sHTG and lifestyle modifications (such as diet and
        exercise) do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients. Approximately 3 million people are living with sHTG in the U.S., including more than 1 million who are considered high risk.
        High-risk sHTG includes those with triglycerides &#8805;880 mg/dL or triglycerides <font style="font-family: 'Times New Roman';">&#8805;</font>500 mg/dL and a history of acute pancreatitis or other comorbidities.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Olezarsen</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Olezarsen is an investigational RNA-targeted medicine being evaluated for the treatment of sHTG. Olezarsen is designed to lower the body&#8217;s production of apoC-III, a
        protein produced in the liver that regulates triglyceride metabolism in the blood. Olezarsen is approved in the U.S. and the European Union as TRYNGOLZA&#174; for adults with familial chylomicronemia syndrome (FCS).</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About Ionis Pharmaceuticals, Inc.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline
        in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep
        understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit <u><font style="font-family: 'Times New Roman';">Ionis.com</font></u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 255);">&#160;</font>and follow us on <u><font style="font-family: 'Times New Roman';">X (Twitter)</font></u>, <u><font style="font-family: 'Times New Roman';">LinkedIn</font></u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 255);">&#160;</font>and <u><font style="font-family: 'Times New Roman';">Instagram</font></u>.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader" style="width: 100%;">
          <div><img src="image00001.jpg"><br>
          </div>
        </div>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Forward-looking Statements</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">This press release includes forward-looking statements regarding Ionis&#8217; business, the therapeutic and commercial potential of our commercial medicines, olezarsen,
        additional medicines in development and technologies, and our expectations regarding development and regulatory milestones. Any statement describing Ionis&#8217; goals, expectations, financial or other projections, intentions or beliefs is a
        forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe
        and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis&#8217; forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to
        differ materially from those expressed or implied by such forward-looking statements. Although Ionis&#8217; forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known
        by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis&#8217;
        programs are described in additional detail in Ionis&#8217; annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are
        available from the Company. In this press release, unless the context requires otherwise, &#8220;Ionis,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; all refer to Ionis Pharmaceuticals and its subsidiaries.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ionis Pharmaceuticals<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and TRYNGOLZA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> are trademarks of Ionis Pharmaceuticals, Inc.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Investor Contact:</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">D. Wade Walke, Ph.D.</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u><font style="font-size: 10pt; font-family: 'Times New Roman';">IR@ionis.com</font></u><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #0000FF;">&#160;</font><font style="font-size: 10pt;">760-603-2331</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Ionis Media Contact:</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Hayley Soffer</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u><font style="font-size: 10pt; font-family: 'Times New Roman';">media@ionis.com</font></u><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #0000FF;">&#160;</font><font style="font-size: 10pt;">760-603-4679</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">###</div>
      <div style="font-size: 10pt;">
        <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ions-20251108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<xs:schema targetNamespace="http://ionis.com/20251108" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ions="http://ionis.com/20251108" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20251108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20251108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ionis.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ions-20251108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ions-20251108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.10.1.5333 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ionis.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20251108.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ionis.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  U *(# 2(  A$! Q$!_\0
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MY/ES6RR$=@5;K^M:5DJM+G.[,HT\=@5BDK-:_P":.?\ VBO^2HWO_7"'_P!
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6]3^-:-%%0W?<PE)R=Y.["BBB@1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IONIS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">&#8220;IONS&#8221;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20058520_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ionis.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20058520_8k.htm">ef20058520_8k.htm</File>
    <File>ions-20251108.xsd</File>
    <File>ions-20251108_lab.xml</File>
    <File>ions-20251108_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20058520_8k.htm": {
   "nsprefix": "ions",
   "nsuri": "http://ionis.com/20251108",
   "dts": {
    "inline": {
     "local": [
      "ef20058520_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ions-20251108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20251108_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20251108_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://ionis.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20251108to20251108",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20058520_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251108to20251108",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20058520_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ionis.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-25-041225-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-041225-xbrl.zip
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M6.G 1%S'&:A2Z#:\4IVH-#B[.%0IX7AA ?DF#*UDT)QQR/^D,N41FND)CQ/
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MM]G)5KX11L5)1(I[98"S1B"+2OVJ,92#KX^E3BRPH8"^F59P ;T&[8+HGM*
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M?7$0=$2#U4RA<C3:+%//P='6"AK>5BB"3] 21,!79A)ZUW/V7;NYY'(7Q_Y
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MR^0&W5G D&9&'C&KNBFXQ2,-"?U()Z7C?LHT-2@ 55DB'+,7$XK\NJWN>(6
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M$B7WL=O%\_]5]+/Q*W_HY%$17M&8Y_2*'L['\ #8-Y.&/X8E\!G-4]8TMJ_
MRY;XXMGW?S/%-:M0U3/+.BUEZ".3C,QN>+@&1"(H"JX4'\&/5KE4GNO:I]ML
MQZP)"(H6W.(]5&:*Y<O7:OD*O$YQA4BQ5_.TO!C0/I!&0VA61M7&E&74\>S
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M[<*O+.&$'Q _.#]$Q!_Q ^U/_P-02P$"% ,4    " "+,&I;:P6Y@^X=  !
MK   $0              @ $     968R,# U.#4R,%\X:RYH=&U02P$"% ,4
M    " "+,&I;[]-!A'X7   "9@  %0              @ $='@  968R,# U
M.#4R,%]E>#DY+3$N:'1M4$L! A0#%     @ BS!J6TQ&]-)" P  ,0\  !$
M             ( !SC4  &EO;G,M,C R-3$Q,#@N>'-D4$L! A0#%     @
MBS!J6TZX63)["   ,58  !4              ( !/SD  &EO;G,M,C R-3$Q
M,#A?;&%B+GAM;%!+ 0(4 Q0    ( (LP:EO2A/^]V04  .P^   5
M      "  >U!  !I;VYS+3(P,C4Q,3 X7W!R92YX;6Q02P4&      4 !0!'
) 0  ^4<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ef20058520_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ions-20251108.xsd" xlink:type="simple"/>
    <context id="c20251108to20251108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2025-11-08</startDate>
            <endDate>2025-11-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20251108to20251108"
      id="Fact_37b826f8738d40f093d8e21c9182402c">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20251108to20251108"
      id="Fact_ef8756b2a2ef48df92e36933c0ad4288">0000874015</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20251108to20251108"
      id="Fact_05178892be8e439aabbac556977de5f1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20251108to20251108"
      id="Fact_347187cf8e3f452888a458032fbbee5c">2025-11-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20251108to20251108"
      id="Fact_91df589377b44bddb2c13d3fbf01b938">IONIS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20251108to20251108"
      id="Fact_1e4475d2a0ac40da8bba94b401cfeb49">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20251108to20251108"
      id="Fact_5c5b1c588ba74e31a6d20bd1ad247fcc">000-19125</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20251108to20251108"
      id="Fact_57264044a1cd4fda8f637207729cdbc2">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20251108to20251108"
      id="Fact_aaf639dcf89844ae90d0b94bf4aab50e">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20251108to20251108"
      id="Fact_1271793cb5dc49f4b7e901e82f1636d4">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20251108to20251108"
      id="Fact_81e71eb71a264fad8a2b4493bc9db53b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20251108to20251108"
      id="Fact_578572ce062d4e1fabb812e2ae2da0dd">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20251108to20251108"
      id="Fact_3fae0ecd90c34a2ca4e5069fcd85b48d">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20251108to20251108"
      id="Fact_c85a84bb1c5b406184a86f22d424e44a">931-9200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20251108to20251108"
      id="Fact_63ac4ec396c845a29951e4ff73af8d5b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20251108to20251108"
      id="Fact_ab125850fa7a4d6c930ab30600fba0af">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20251108to20251108"
      id="Fact_aac0b40c95ab4fb8b15eafa6642d8469">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20251108to20251108"
      id="Fact_40fe8b118416410e92196a5a2a278dad">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20251108to20251108"
      id="Fact_423e1f035e3d45a792e5ba004bf305d4">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20251108to20251108"
      id="Fact_83c39807ed884f4b86170a1d4278c3be">&#x201c;IONS&#x201d;</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20251108to20251108"
      id="Fact_f82124cde5d642b38793d066fee4d151">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20251108to20251108"
      id="Fact_9627e1bb0d8346f1b94d0a2a0cd0096e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
